BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
Want to see BBOT full AI Analyst Report?
Top Page
BridgeBio Oncology Therapeutics
(NASDAQ:BBOT)
Select Model
Select Model
Rating:46Neutral
Price Target:
$8.50
▼(-32.49% Downside)
Action:ReiteratedDate:04/24/26
The score is primarily constrained by weak financial performance (pre-revenue, widening losses, and heavy cash burn), partially offset by a strong, low-debt balance sheet that can fund continued development. Technicals add a further headwind with the price below key moving averages and negative MACD, while valuation is limited by a loss-making profile and no dividend. A positive corporate event (leadership overhaul) modestly improves the outlook on execution.
Positive Factors
Balance Sheet Strength
A well-capitalized balance sheet with very low leverage gives BBOT durable financial flexibility to fund multi-year oncology R&D without immediate debt pressure. This reduces short-term refinancing risk and supports sustained pipeline investment and strategic partnerships over the next several quarters.
Negative Factors
High Cash Burn
Substantial negative operating and free cash flows indicate ongoing heavy funding needs to advance trials. Over mid-term horizons this raises dilution and financing risk, forcing dependence on equity or partnership capital and potentially constraining strategic optionality if markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A well-capitalized balance sheet with very low leverage gives BBOT durable financial flexibility to fund multi-year oncology R&D without immediate debt pressure. This reduces short-term refinancing risk and supports sustained pipeline investment and strategic partnerships over the next several quarters.
Read all positive factors
BridgeBio Oncology Therapeutics (BBOT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$717.89M
Dividend YieldN/A
Average Volume (3M)344.97K
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees62
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding80,032,820
10 Day Avg. Volume232,276
30 Day Avg. Volume344,973
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-3.41
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.79K
Enterprise Value/Ebitda-2.39
Forecast
1Y Price Target
$25.57Price Target Upside103.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BridgeBio Oncology Therapeutics Business Overview & Revenue Model
Company Description
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidi...
How the Company Makes Money
BridgeBio Oncology Therapeutics generates revenue primarily through the commercialization of its oncology drug portfolio, once they are approved by regulatory agencies. Additional revenue streams may include licensing agreements, partnerships with...
BridgeBio Oncology Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -610.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -145.82M | -80.66M | -64.68M | -3.52K | -43.36K |
| Net Income | -134.04M | -74.28M | -64.70M | -3.52K | -43.36K |
Balance Sheet | |||||
| Total Assets | 448.38M | 194.42M | 332.89K | 144.58K | 144.28K |
| Cash, Cash Equivalents and Short-Term Investments | 425.46M | 1.70M | 0.00 | 0.00 | 0.00 |
| Total Debt | 2.77M | 0.00 | 70.09K | 43.11K | 36.96K |
| Total Liabilities | 37.28M | 5.71M | 396.46K | 166.46K | 162.64K |
| Stockholders Equity | 411.10M | 188.72M | -63.57K | -21.88K | -18.36K |
Cash Flow | |||||
| Free Cash Flow | -114.50M | -763.82K | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow | -113.89M | -763.82K | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | 73.33M | -184.00M | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 383.40M | 186.46M | 0.00 | 0.00 | 0.00 |
BridgeBio Oncology Therapeutics Risk Analysis
BridgeBio Oncology Therapeutics disclosed 93 risk factors in its most recent earnings report. BridgeBio Oncology Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BridgeBio Oncology Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
BBOT
BridgeBio Oncology Therapeutics
8.97
-1.83
-16.94%
FORL
Four Leaf Acquisition Corporation Class A
11.00
-0.27
-2.35%
QETA
Quetta Acquisition Corp.
11.50
0.76
7.08%
BridgeBio Oncology Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
BridgeBio Oncology Overhauls Leadership for Next Development Phase
Positive
Apr 23, 2026
On April 22, 2026, BridgeBio Oncology Therapeutics announced a leadership overhaul effective April 20, 2026, appointing former Chief Scientific Officer Pedro J. Beltran, PhD, as Chief Executive Officer and elevating former Senior Vice President of...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.